Amgen - CRUSH Report - 09B2

!
Amge n Inc.
1 Amgen Center Drive Thousand Oaks, CA 91320-1799 Main: 805-447-1000 Fax: 805-447-1010 www.amgen.com Annual Revenues $15.0 Billion Fiscal Year End December Employees 17,500 Ticker Symbol (NASDAQ) AMGN Industry Pharmaceuticals
INFORMATION TECHNOL OGY HIGHLIGHTS
Enterprise Applications o ACT1 Group managed services and human resource solutions o Ariba 8.1, Spend Management o Callidus TrueComp 3.7 sales performance management o CSC FirstDoc R&D 4.3, 6.0 o EMC Documentum o HP Peregrine Service Desk o IBM Lotus Notes, Mobile Notes o IBM MRO Maximo Enterprise Asset Management o Microsoft Exchange 2007 Enterprise Edition, Unified Messaging o Microsoft Outlook o Open Text Livelink Enterprise Content Management (ECM) o Oracle JD Edwards o Oracle Siebel Pharma Dynamic Sales, Customer Relationship Management (CRM) o SAP R/3, ERP Central Component (ECC) 5.0, 6.0: Accounts Payable (AP), Accounts Receivable (AR), Advanced Planner and Optimizer (APO), Asset Management (AM), Capable-to-Match (CTM) Planning, e-Recruit 6.0, Financial Accounting and Controlling (FI/CO), General Ledger (GL), Human Resources (HR), Human Capital Management (HCM), Livecache 7.6, Materials Management (MM), Organizational Management (OM), Performance Management (PM), Personnel Administration (PA), Project Systems (PS), Sales and Distribution (SD), Strategic Enterprise Management (SEM), Supplier Relationship Management (SRM) 4.0, Supply Chain Management (SCM) 5.0, Warehouse Management (WM), o Smeadlink Integrated Document Management o Werum PAS-X Manufacturing Execution Systems (MES) 2.4 to 3.09 Data Management & Business Intelligence o Actuate business intelligence7.1, 8.1 o Brainware Data Solutions o Emerson DeltaV Digital Automation System o IBIM Informix o IBM Cognos for Business Intelligence (BI) and Data Warehousing (DW) o IBM Cognos PowerPlay Enterprise Server, Impromptu, IWR, Upfront
!
" 2009 Sal esQu est . CorporateCRUSH is a trademark of SELIGENCE LLC. www.SalesQ uest.co m
o Informatica PowerCenter 7.1.2, 8.0 o Informatica PowerConnect for SAP ECC and BW 8.1.1 o Microsoft Access o Microsoft SQL Server 2000, 2005 o Oracle Database 9i, 10g o Oracle Hyperion Brio Intelligence 6.6 o Oracle Virtual Directory o Pegasystems Business Process Management Software Solutions o Rockwell Supervisory Control and Data Acquisition (SCADA) o SAP Content Server 6.4 o SAP NetWeaver Business Explorer (BEx) o SAP NetWeaver Business Information Warehouse (BW) o SAP NetWeaver Business Intelligence (BI) 3.5, 7.0 o SAP NetWeaver Mater Data Management (MDM) o SAS BASE 9.1.2, GRAPH, MACRO, STAT o Teradata o TIBCO 5.2 Hardware/OS/Systems Environment o Avaya Octel message servers o Bay Networks BCN Routers o Cisco 2800, 3600, 3800, 7200 series routers o Cisco Catalyst 2900, 3750, 6500 switches o Cisco CatOS o Cisco Content Services Switch (CSS) o Cisco Unified Messaging o Cisco Unified Wireless Network o HP Integrity rx2620 family servers o HP ProLiant DL385 high efficiency rack servers o IBM AS/400 o IBM iSeries o Microsoft Active Directory o Microsoft Business Desktop Deployment (BDD) 2007 o Microsoft Live Communications Server 2005 o Microsoft Windows Driver Kit (WDK) 5.3, 6.5 o Microsoft Windows NT, 2000, XP o Microsoft Windows Server 2003, XP o Microsoft Windows Terminal Server o NetApp filers, storage o Nortel Contivity 1000, 2500, 4000 VPN o Nortel PBX o Nortel Unified Messaging o Quantum Scalar i2000 tape library o Red Hat Linux o Sun Enterprise 3500, 4500, 6500, 220R, 420R, o Sun Fire V-Series servers o Sun Netra Carrier-Grade Server o Sun Solaris 8, 9 o Sun Ultra series Web Services & Application Development o AJAX o Aldon Application Lifecycle Manager
!
o Apache Ant, Tomcat 5.5 o BCD Catapult automated e-mail, portal o CA AllFusion ERwin 4.1 o Eclipse 5.5 o EMC Documentum Application Builder 5.3, WebTop o HP Mercury Quality Center o IBM Rational Rose, RequisitePro o J2EE o Java Database Connectivity (JDBC) o Java, JavaScript o Microsoft .NET Framework: ASP.NET, VB.NET o Microsoft ActiveX o Microsoft BizTalk o Microsoft C# o Microsoft Internet Information Services (IIS) o Microsoft Office SharePoint o Microsoft Visual Basic (VB) 6.0 o Microsoft Visual Basic Application o Microsoft Visual SourceSafe (VSS) o Microsoft/Sybase T-SQL o Oracle Applications Database o Oracle BEA Plumtree o Oracle BEA WebLogic 8.1 o Oracle PL/SQL o Perl, Windows Scripting Host o SAP Advanced Business application Programming (ABAP) o SAP Exchange Infrastructure (XI) Messaging o SAP NetWeaver Enterprise Portal: Internet Pricing and Configurator (IPC) o SAP TREX 7.0 search engine o SilkRoad Eprise Web Content Management o Sparx System Enterprise Architect 7.0 o Sun Java System Directory o Sun Java System Web Server 6.1 Networking, Management & Security o CA Concord Communications IT management o Captaris RightFax 8.0 o Cisco Aironet 1242G Wireless access point o Cisco CallManager VOIP 4.1, 6.0 o Cisco IP Contact Center (IPCC) Infrastructure o Cisco Unity o Cisco VoIP Telephony o Cisco Web-VPN o ExtraView bug tracking and issue management platform o Geomant Message Waiting Indicator (MWI) 2007 for Microsoft Exchange Server 20007 and Unified Messaging solutions o HP OpenView (replaced HP Peregrine Systems) o IBM Tivoli Access Manager Administrator o Infoblox IP Address Management o Intelex Safety Management System, iForms o Juniper NetScreen Secure Services Gateway Firewal (SSG) 540, 550, Security Manager
!
o Microsoft Virtual PC o NettApp Decru storage security o OSIsoft PI Data History o Raritan Command Center network monitoring o SAP Solution Manager o SAP Virsa compliance o Sendmail secure messaging infrastructure o Symantec Veritas NetBackup, Volume Manager o VMware virtualization Other Technologies, Applications & Business Initiatives o Adobe Reader 7.00 o Amgen Biostatistics Departments Submission Data File (SDF) System o Amgen Call Center based in Thousand Oaks, Calif. o Amgen Data Centers based in Thousand Oaks, Calif. and West Greenwich, R.I. o Amgen Global Enterprise Resource Planning Program Integration o Amgen Global Opinion Leader Engagement System Data Operations Lead, CRM Application o Amgen Information Technology Facility Juncos, Puerto Rico o Amgen Research and Design Strategic Operations Outsourced to India o Amgens in-house Competitive Intelligence Application o ARCHIBUS Total Infrastructure and Facilities Management o Autodesk AutoCAD o Commercial Programming Systems (CPS) IT hiring o CompuCom IT Reorganization Contracting o HP Mercury e-signature functionality development o IBM 5-year, $500 million Information Systems Infrastructure Services Contract o Information Technology Infrastructure Library (ITIL) o Jones Lang LaSalle Americas Facilities Management Services Contract o Kling Stubbins architecture engineering project consulting o Maynard consulting: Engineered Standards Implementation o Microsoft Office Live Meeting o Microsoft Office Suite, Vista o PointRoll Web Site development o Quest America Database Administration and Maintenance Services o SAP Global Trade Services (SAP GTS o Shelby Group Strategic Software Consulting o Software Development Life Cycle (SDLC) o Vision Soft IT asset management consulting
IT SPOTLIGHTS
Glob al E nter pri se Re so urce Pla nni ng P ro gra m Amgen implemented a Global Enterprise Resource Planning (G-ERP) Program to increase Amgens productivity and enable improved decision-making by creating new business processes that are global, standardized, cross-functional, and scalable. G-ERP is transforming approximately 800 business processes in the areas of Human Resource, Finance, Supply Chain, Procurement and Customer Order to Cash spanning 45 countries including North America, Europe, and Australia and more than 18,000 employees, using a single instance of SAP. There have been approximately 150
!
Amgen staff members and 120 IBM consultants dedicated full-time to this program over the last 33 months. The G-ERP Program will allow Amgen to realize five key benefits: Improved data integrity and accuracy by creating a single source of information Real-time access to information, enabling timely decision-making Improved efficiency and scalability through automated business processes Reduced effort to meet compliance requirements Streamlined software portfolio, reducing maintenance costs.
As part of the G-ERP Program the SAP system is being completely integrated with 86 other Amgen core systems. Amgen decided to adopt the SAP NetWeaver platform together with the SAP Exchange Infrastructure to develop systems. They implemented SAPs Human Resources module to standardized and automate existing HR processes and forms throughout the company including SAPs E-Recruiting module which was introduced to support the way Amgen recruits talent globally. Amgen is one of the first SAP customers to make extensive usage of the SAP XI Messaging infrastructure to enable integration with other systems using a services oriented architecture (SOA). Further breakdown of the Global Enterprise Resource Planning Program in the IT Development section on Pages 10-13 or visit http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031 IBM Inf ormati o n Systems I nf rast ructure Service s Co nt ract IBM has signed a five-year, $500 million deal with Amgen to provide IT services including computer networks, software, messaging systems, and help desk support. IBM could get an additional $300 million if three extension contracts are exercised. The agreement will impact about 100 Amgen employees and the Thousand Oaks, Calif.-based companys 60-plus sites, Amgen spokesman David Polk said, adding that the affected employees will be given an opportunity to work with IBM. Kli ng St ubbi ns has wo rke d o n p rojects a re t he f oll owi ng locati o ns:

Amgen AR6 Data Center design infrastructure build out West Greenwich, RI. Amgen Data Center upgrades Thousand Oaks, Calif. Amgen Information Technology Facility concept design Thousand Oaks, Calif. Amgen Information Technology Facility Juncos, Puerto Rico.
Resea rch and Des ig n Strate gic O perati o ns Out s ource d to I ndia In 2006, under the gun to increase productivity, Amgen opened up affiliates in Mumbai and Hong Kong. Its Mumbai operation will support trials in India while Hong Kongs serves as a regional hub for operations in East Asia. Amgen says it is partnering with companies in India and China to support its R&D operations, but wont divulge what its investing in Asia. Co mp uCom I T Re or ga ni zatio n C ont racti ng CompuCom was contracted to help reorganize part of the IT department to achieve optimal service and revenue generation. CompuCom contractors worked to troubleshoot and provide solutions for network bottlenecks and network slow downs, and provided solutions for end users by successfully assisting with hardware and software issues. Contractors worked with teams to initiate policies and procedures for inventory control, resulting in saving $150,000 in labor costs on a yearly basis, and increased assets by $250,000 by tracking inventory more efficiently. This radically increased customer service rating by developing and empowering the technical staff.
!
Glob al IS I nf rast ruct ure St rateg ic S o urc ing Pro g ram A 54 person IT team transitioned the companys global IS infrastructure functions, processes and employees the Amgens outsourcing vendors. This project had a total budget of $6 million. Glob al U nifie d C olla bo rati o n Depl o yme nt An Amgen in house team consisting of 13 team members worked with 3rd party vendors to design and implement Ciscos Unified Messaging, e-faxing, and Instant Messaging into the Microsoft Exchange and Outlook environment. The project required collaboration with Legal, Compliance, Helpdesk and Training organizations to ensure effective operational support and avoid misuse of the new technology The project ran a budget of approximately $2.9 million and resulted in annual cost savings of approximately $1.44 million. Cis co Call Manage r V oIP a nd I P CC (Co ntact Ce nter) Infra struct ure U pg rade A team of eight infrastructure analysts made up the Cisco Technical Services team that performed the upgrade of Cisco Call Manager 4.1 to Call Manager 6.1. The upgrade provided enhanced functionality to the existing VoIP users and call center environments and ensured compatibility with the Unified Messaging solution. The project costs amounted to $600,000. Manufact ur ing Data Ma na geme nt (MDM) I nteg ra tion A seven member project team integrated regulated data from 5 manufacturing source systems, including PI and WERUM PAS X, through a virtual data warehouse using the SAP XMII platform. The solution provided consolidated, regulated Good Manufacturing Procedures (GMP) data reports for the entire product manufacturing process at each U.S. manufacturing facility. The project budget was approximately $688,000. Tier III Data Cente r a nd East Coa st Reg i onal Hea d Off ice IS Inf ra structure Impleme ntatio n The tier III data center design and construction project had a budget of $4.9 million and a team of 18 analysts. The project tasks included:

IS computer and server rooms Network infrastructure (wired and wireless) implementation Site cabling infrastructure (redundant fiber and copper) Telephony and voicemail systems Cabling offices, cubes, Audio Visual (A/V) conferencing systems
Data Ce nt Upg ra des a nd Se r ver R eloc atio n The project had a budget over $200,000 in which a team of 10 analysts managed the IS activities for the new construction and upgrade of data centers. They provided highly reliable, fault tolerant (n+1), and scaleable environments (Tier II/III) for hosting business critical systems. The team relocated over 250 servers between data centers, re-qualification, and validation with ITIL based change management processes. Enterprise W o rkfl ow M ana geme nt System De vel opme nt a nd Ma inte na nce P roject Beginning in 2008, this project deals with the design and development of enterprise workflow management systems. The workflow management system manages the different phases through which an Issue or a Tracking record traverses, before it gets final status. Commercial Off the Shelf (COTS) solution ExtraView is used for defining and managing the workflows. The ExtraView is a metadata driven J2EE application with Java extensions using UserCustom classes. Technologies and tools used during this project include Java, J2EE, HTML, JavaScript, AJAX, JDBC, Windows, Active Directory, LDAP Browser, Oracle BEA WebLogic 9.2, Apache Tomcat 5.5, Oracle Database 10g, Eclipse 3.4.1, ExtraView, UML, Sparx Enterprise Architect 7.0, Unix and Shell scripting.
!
Glob al Op inio n Lead er E ngag eme nt (G OLE) a nd CRM Ap plicati o n The Global Opinion Leader Engagement (GOLE) solution provides a single repository and approach for sharing information about who Amgens opinion leaders are and how these individuals are being engaged across the company. The GOLE Operation teams were responsible for providing first line support to maintain steady state operations of the Global Opinion Leader application and associated environments. They designed and developed the GOLE Application using .Net and J2EE technology. The team managed the data base extract processes and designed DTS to extract external data. The technology environment of this project was comprised of VB.Net, ASP.Net, C#, SQL server, Oracle Database 10g, PL/SQL, Oracle 9i Client, XML, XSD, Java and J2EE.
BUSINESS INFORMATION
Amgen Inc., incorporated in 1980, is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). Aranesp and EPOGEN stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (ESAs). On Jan. 4, 2008, the company completed the acquisition of Dompe Biotec, S.p.A. Aranesp is used for the treatment of anemia both in supportive cancer care and in nephrology. EPOGEN is used to treat anemia associated with chronic renal failure (CRF). Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, one type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting its binding to TNF receptors, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. During the year ended Dec. 31, 2008, its principal products represented 94 percent of total product sales. The company maintains sales and marketing forces primarily in the United States, Europe and Canada. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. It markets ENBREL under a co-promotion agreement with Wyeth in the United States and Canada (Joint Ventures and Business Relationships-Wyeth). In addition, it has entered into licensing and/or co-promotion agreements to market its products in certain geographic areas. In the United States, the company sells primarily to wholesale distributors of pharmaceutical products. Outside the United States, it sells principally to hospitals and/or wholesalers depending upon the distribution practice in each country. The company focuses its research and development (R&D) efforts on therapeutics for the treatment of grievous illness in the core areas of oncology, inflammation, bone, metabolic disorders and neuroscience. Its research takes a modality-independent approach to drug discovery, in which it chooses the possible approach to block a specific disease process before considering the type of drug (modality) that may be required to pursue that approach. It studies molecules across a range of modalities in the areas of proteins (sometimes referred to as large molecules), including monoclonal antibodies and peptibodies, and small molecules. It has major R&D centers in several locations throughout the United States and in the United Kingdom, as well as, smaller R&D centers in certain other countries throughout the world.
!
The companys manufacturing operations consist of bulk manufacturing, formulation, fill and finish activities, which produce Aranesp, Epoetin alfa, Neulasta, NEUPOGEN, ENBREL and other marketed products and product candidates for both commercial and clinical purposes. It operates commercial and clinical manufacturing facilities in several locations throughout the United States and in Puerto Rico, as well as performs certain finishing activities in the Netherlands. Third-party contractors manufacture some or all of certain of its marketed products and/or product candidates. Ara ne sp Aranesp is the companys registered trademark for one of its erythropoiesis-stimulating proteins, a protein that stimulates red blood cell production. The company was granted a license by KirinAmgen, Inc. (KA), a joint venture between Kirin Holdings Company, Limited (Kirin) and Amgen, to manufacture and market darbepoetin alfa in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, North Africa and the Middle East. It markets Aranesp primarily in the United States and Europe. Darbepoetin alfa is also marketed under the brand name Nespo in Italy. EPO GEN EPOGEN is the companys registered trademark for its recombinant human erythropoietin product, a protein that stimulates red blood cell production. It was granted a license to manufacture and market recombinant human erythropoietin in the United States under a licensing agreement with KA. The company markets EPOGEN for the treatment of anemic adult and pediatric patients with CRF who are on dialysis. Ne ulasta (pe gfil g rastim )/ NEU POG EN (Fil gra stim ) Neulasta is its registered trademark for a pegylated protein that selectively stimulates production of certain white blood cells known as neutrophils and is based on the Filgrastim molecule. It markets Neulasta and NEUPOGEN primarily in the United States and Europe. NEUPOGEN is the companys registered trademark for its recombinant-methionyl human granulocyte colony-stimulating factor (GCSF), a protein that selectively stimulates production of of neutrophils. It markets NEUPOGEN primarily in the United States, Europe and Canada. Filgrastim is marketed under the brand name GRANULOKINE in Italy. Filgrastim is also marketed under the brand name GRANULOKINE in Italy. Enb rel ENBREL is the companys registered trademark for its TNF receptor fusion protein that inhibits the binding to TNF receptors, which can result in a significant reduction in inflammatory activity. It markets ENBREL under a co-promotion agreement with Wyeth in the United States and Canada. Othe r The companys other marketed products comprises Sensipar (cinacalcet), Vectibix (panitumumab) and Nplate (romiplostim). Sensipar is the companys registered trademark in the United States and Mimpara is its registered trademark in Europe, for the companys first small molecule medicine used in treating CKD patients on dialysis who produce too much parathyroid hormone, a condition known as secondary hyperparathyroidism. Vectibix is the companys trademark for its first entirely human monoclonal antibody for the treatment of patients with Epidermal Growth Factor Receptors (EGFr) expressing metastatic colorectal cancer (mCRC) after disease progression on, or following fluoropyrimidine-, oxaliplatin- and irinotecan- containing chemotherapy regimens. On Aug. 22, 2008, the Food and Drug Administration of Untied States (FDA) approved Nplate, the platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the FDA approved peptibody protein, works by raising and sustaining platelet counts. On Feb. 6, 2009, the company announced that the European Commission granted marketing authorization for Nplate for
!
the treatment of splenectomized adult chronic ITP patients who are refractory to other treatments (such as corticosteroids, immunoglobulins). The company competes with Johnson & Johnson, Hospira Enterprise B.V., Stada Arzneimittel AG, Sandoz GmbH, Hexal Biotech Forschungs GmbH, Medice Arzneimittel Putter GmbH & Co. KG, F.Hoffmann-La Roche Ltd., Shire Pharmaceutical Group Plc, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceuticals Co., Ltd., Sanofi-Aventis Novartis AG, Ratiopharm, CT Arzneimittel, Teva, Procter & Gamble, Eli Lilly and Company, Merck & Company, Inc., Centocor, Inc., Schering Plough Corporation, Abbott Laboratories, Duramed Pharmaceuticals, Inc., DAVA Pharmaceuticals, Inc., Genentech, Inc., Biogen IDEC Inc., Genzyme Corporation and Connetics Corporation.
EARNINGS CALL TRANSCRIPT

Kevin Sharer, Chairman and Chief Executive Officer April 23, 2009. We all know we are in the midst of the most challenging economic environment in 80 years. We also now know that for the first time the biopharmaceutical industry is not exempt from these economic factors in the United States. In America patients are sometimes postponing doctor visits, not always taking medicines on the prescribed schedule and in some cases, particularly Enbrel in our case, are finding the co-pays difficult to afford. We also know that health and insurance coverage is not as broad or robust as in prior non-recessionary years. We will talk about these factors later in the call, with particular emphasis on the aggressive steps we are taking to help patients afford their medicines. Now, I would like to focus on the first quarter revenue and our perspective about the rest of the year. It is a normal cyclical pattern at Amgen to have the fourth quarter be stronger than the first. For example, in both 2007 and 2008 the first quarter revenue was 4 percent below the prior fourth quarter. This year the difference is 12 percent. Looking more deeply, in both 2007 and 2008s first quarter demand was down approximately $147 million from the prior quarter. This year demand is down about $214 million fourth quarter to first quarter, with the difference between this and prior years numbers due to negative Enbrel trends. We also experienced an inventory swing fourth quarter 08 to first quarter 09 of $176 million, that is we were up $61 million fourth quarter 08 and down $115 million in Q109 that accounts, along with the Enbrel drop, for the vast majority of the total quarterly drop in revenue. Clearly Enbrel is a major challenge and George will provide more detail later. Our revenue plan is the basis for our revenue guidance and I will now put my view of our business in a context of our plan. Our international business is strong, doing well against biosimilars, and should be on or above plan for the year. While EPOGEN is a bit behind plan to date, we expect dose recovery and a modest price increase to help it achieve budget for the year. http://seekingalpha.com/article/132813-amgen-inc-f1q09earnings-call-transcript?page=-1
STRATEGY
Amgens strategy includes putting patients first, focusing solely on human therapeutics, investing heavily in their pipeline, fostering a high-performing and diverse workforce grounded in their values, remaining independent by delivering superior value to their stockholders, and striving to be a leader in every therapeutic area they serve.
!
On Aug. 15, 2007, they announced a plan to restructure their worldwide operations in order to improve their cost structure while continuing to make significant R&D investments and build the framework for their future growth. Through Dec. 31, 2008, they have completed substantially all of the actions initially included in their restructuring plan, including the divestiture of certain less significant marketed products discussed below. During 2008, they identified certain additional initiatives designed to further assist in improving their cost structure, including outsourcing certain non-core business functions, most notably certain of their information systems infrastructure services, as well as abandoning leases for certain additional facilities that will no longer be used in their operations. As part of the restructuring plan, they reduced staff, made changes to certain capital projects, closed certain production operations and abandoned leases primarily for certain R&D facilities that will not be used in their operations.
IT EXPENDITURES
Capital expenditures totaled $672, $1.3 billion, and $1.2 billion for the years 2008, 2007, and 2006, respectively. Capital expenditures for the three years were primarily associated with manufacturing capacity expansions and other site developments and investment in the companys global ERP system and other information systems projects. They estimate 2009 spending on capital projects and equipment to be approximately $700 million. Selling, general and administrative expenses totaled $3.8 billion, $3.4 billion, and $3.4 billion for the years 2008, 2007, and 2006, respectively. During 2008, they identified certain additional initiatives designed to further assist in improving their cost structure, including outsourcing certain non-core business functions, most notably certain of their information systems infrastructure services, as well as abandoning leases for certain additional facilities that will no longer be used in their operations. The estimated cost of these additional initiatives is $95 million to $135 million. The total charges currently estimated to be incurred in connection with their restructuring plan, including related implementation costs, is $950 million to $985 million. Through Dec. 31, 2008, they have incurred $887 million of these costs and currently estimate that all remaining costs will be substantially incurred in 2009.
IT DEVELOPMENTS
Glob al E nter pri se Re so urce P la nning Pro gram, S AP, EC C 5.0: S up plie r Relatio ns hi p Ma na geme nt (S RM) 4. 0, E- Recruit 6.0, c Fol ders 3.1 0, S CM 5. 0, I P C 4, Str ategic E nter pr ise Ma na geme nt (S EM), CT M 5. 0; S AP NetWea ve r 7. 0, Enter pr ise P ortal (E P) 6. 0, Busi nes s I nf orma tion Wa reho us e (BW) 7. 0; S A P Co nte nt Se r ver 6. 4, XI 3. 0, Li vecac he 7. 6, T REX 7. 0, Sol uti o n Ma nage r 4.0, Glob al T rad e S ystem (G T S) 7. 0; A do be 7 .00; I nf ormatica Pow erC onnect Integ ratio n fo r EC C and B W; TIB CO 5. 2; Mic ros oft SQ L Se rver 2 0 05, Wi nd ow s Serve r 2 0 03 Amgen implemented a Global Enterprise Resource Planning (G-ERP) Program to increase Amgens productivity and enable improved decision-making by creating new business
!
10
processes that are global, standardized, cross-functional, and scalable. The G-ERP Program will allow Amgen to realize five key benefits:

Improved data integrity and accuracy by creating a single source of information Real-time access to information, enabling timely decision-making Improved efficiency and scalability through automated business processes Reduced effort to meet compliance requirements Streamlined software portfolio, reducing maintenance costs.
G-ERP is transforming 800 business processes in the areas of Human Resource, Finance, Supply Chain, Procurement and Customer Order to Cash spanning 45 countries (North America, Europe, Australia) and more than 18,000 employees, using a single instance of SAP. There have been approximately 150 Amgen staff members and 120 IBM consultants dedicated full-time to this program over the last 33 months. Usage of technology (infrastructure, software, network, etc.) has been a key component of the G-ERP Program. The ERP solution includes the implementation of nearly all modules of SAP using a single instance in production to support Amgen globally that serves as a foundation for the process and efficiency improvements needed to better ensure uninterrupted patient supply. The software components included as part of the ERP solution include:
Within SAP: SAP NetWeaver 7.0, ECC 5.0, GTS 7.0, SRM 4.0, eRecruit 6.0, cFolders 3.10, SM (Solution Manager) 4.0, SCM/APO 5.0, IPC 4, BW 7.0, SEM, Livecache 7.6, CTM (APO optimizer) 5.0, Content Server 6.4, XI 3.0, EP 6.0, TREX 7.0 Outside of SAP: Adobe 7.00, Informatica PowerConnect Integration (for ECC v7.1.4, for BW v8.1.1), TIBCO 5.2, Microsoft SQL Server 2005 and OS Windows Server 2003
(Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031
Glob al Ente rp ris e Res ource Pla nni ng Prog ram I nteg rati on, S AP NetWea ver, SA P Exc hange Inf ra str ucture, S ol utio n Ma na ger, H P Me rc ury Q ualit y Ce nter, Vi rsa , Cra nber r y B ack O ffice S ystem As part of the G-ERP Program the SAP system is being completely integrated with 86 other Amgen core systems. Amgen decided to adopt the SAP NetWeaver platform together with the SAP Exchange Infrastructure to develop systems. In addition to the technology components used as part of the ERP solution, technology (usage of different tools) was important to better manage the program processes and documentation. Some of the key tools used at Amgen for the G-ERP Program include:
SAP Solution Manager (SolMan) managed in process project documentation (e.g., design specifications, process flows, configuration documentation, data conversion protocols); was also used to manage the transport process of code and configuration to the various system environments (e.g., from Development to Integration Test, Operation Qualification, Staging, Training, Production) Mercury/HP Quality Center (QC) served as the repository for User Requirements. Test documentation (e.g., Test scripts, defects). Was leveraged heavily by the program management team to manage the testing process (with real-time status/metrics reporting). QC also serves as the repository for the traceability matrix which is a required deliverable for FDA Computer System Validation.
!
11
Virsa manages SAP security roles and flags any segregation of duties violations and risks. Back Office System Cranberry tool improved data conversion process by enabling a more streamlined way to extract, adjust, upload and reconcile data being loaded into SAP
Amgen architected the G-ERP system infrastructure to enable Disaster Recovery (data replication across multiple locations). Amgen performed failover and failback tests that were very successful. This DR solution gives Amgen a Recovery Point Objective (RPO = how much data they will lose in case of a disaster) of zero and a Recovery Time Objective (RTO = how long it will take to be back up and running) of 4 hours. This further reduces improves Amgens ability to ensure uninterrupted patient supply. (Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031
Glob al E nter pri se Re so urce Pla nni ng P ro gra m, SA P H uma n Re so urces Mo dule Amgen implemented SAPs Human Resources module to standardized and automate existing HR processes and forms throughout the company. The G-ERP system is used by every Amgen employee in the company for performance objectives/reviews and updating their some personnel-related information using the self-service portal. All Amgen staff now has a central place to find their position history and salary history on-line. Staff also now has access to all of their (current and historical) performance reviews and leverage as appropriate for professional development and future performance reviews, saving both time and effort. (Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031 Glob al E nter pri se Re so urce Pla nni ng P ro gra m, SA P E-R ecruiti ng Mo d ule SAPs E-Recruiting module was introduced to support the way Amgen recruits talent globally. The applicant tracking system allows Amgens Human Resources department to manage the processing of applicants and track their progression. Additionally, having a global applicant tracking system gives visibility into all recruiting and hiring across Amgen. E-Recruiting also supports internal movement within Amgen. E-Recruiting will assist us in gaining access to potential candidates globally and increase our efficiency in the management of these candidates, said Jill Rogers Executive Director, HR. The launch was very smooth in fact, we were able to handle record volumes the day after go-live. I deeply appreciate the hard work by so many around the world to make this happen, said Rolf Hoffman, then Senior Vice President, International Commercial Operations for Amgen. ( Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031 Glob al E nter pri se Re so urce Pla nni ng P ro gra m, SA P XI Mess agi ng Infra struct ure Amgen is one of the first SAP customers to make extensive usage of the SAP XI Messaging infrastructure to enable integration with other systems using a Services Oriented Architecture (SOA). In the case where SAP needs to send data to other Amgen systems, master data and transactional is exposed via pull-based query interfaces directly from SAP using BI reports, ECC Reports, or Amgens Enterprise Data Hub (EDH) utilizing common Web services via SAP XI. (Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031 Glob al E nte rp rise Re so urce Pla nni ng Pro gram, H P Merc ury Q ual ity C ente r, eSig nat ure Amgen operates in a highly regulated environment. In order to best leverage the global team Amgen leveraged an automated testing tool, Mercury Quality Center. There were two aspects of
!
12
Amgens usage of QC which are unique, both of which required custom development by Mercury Interactive to enable the new functionality which has only been done for Amgen. e-Signature: In order to be 21 CFR Part 11 compliant (a requirement of FDA Computer System Validation), Amgen asked Mercury Interactive to build in electronic signature functionality (to replace a wet-ink signature on a hard copy test script). This significantly reduced effort, cost and time during the testing process as compared to other SAP implementations at Life Sciences companies. With the broad functional and geographic scope of the G-ERP program and high volume of Qualification test scripts (>3,000 for Global HCM/Europe and >5,000 for North America), the testing process would have been significantly delayed if the G-ERP team used the manual test documentation approach (e.g., Fed Exing test scripts back an forth between the US & Europe for wetink signatures upon completion of each test step in the 80 step script). Traceability Matrix: This is a required deliverable as part of FDA Computer System Validation. Amgen asked Mercury Interactive to build in a link between the User Requirement and Test objects so that the Traceability matrix would be made available on-line and real-time (vs. needing to maintain manually in a separate document like MS Word, Excel which is how most other Life Sciences have documented their Traceability matrix). (Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031
IBM Inf ormati o n Systems I nf rast ructure Service s Co nt ract In 2008, IBM signed a deal worth up to $800 million to provide information systems infrastructure services to Amgen. IBMs work will span services such as networks, help desk support, servers hosting applications and electronic messaging systems under the deal that could climb to $800 million if Amgen extends the contracts terms by three years, according to a filing Amgen made with the Securities and Exchange Commission. The agreement will impact about 100 Amgen employees and the Thousand Oaks, Calif.-based companys 60-plus sites, Amgen then spokesman David Polk said, adding that the affected employees will be given an opportunity to work with IBM. http://www.metrodenver.org/news-center/metro-denver-news/IBM-Amgen.html Amg en S ubm is sio n Data Fil e (SD F) S ystem, S AS , Java, a nd O racle A number of years in the making, the SDF System represents the most ambitious software development project ever undertaken within the Biostatistics Department at Amgen. From its inception it was designed to tackle many of the difficulties that have plagued statistical programming ever since the first programs were developed to analyze clinical trial data. The system scope includes the following areas:

Automating front-end and back-end data security. Providing rapid access to raw and derived datasets to all sites within the organization. Implementing large-scale systems design and software engineering principles in the clinical trials programming domain to reduce the software development effort required for each statistical analysis. Modeling the complex relationships inherent within clinical data to provide sophisticated impact analysis tools with the capability to manage and cascade change. Implementing an object-oriented (OO) approach to the definition and reuse of clinical data standards. Improving review and quality control processes by coupling the specification of a program together with its source code to create one logical entity.
!
13
Reducing the validation burden (through large-scale reuse) while at the same time increasing overall quality.
The Submission Data File System (SDF) was designed to support the development, validation, maintenance and execution of SAS programs required to create Submission Data Files (SDFs). The system leverages a number of key technologies including SAS, Java, and Oracle. (Article dated 2006.) http://www.lexjansen.com/phuse/2006/ad/ad12.pdf
Jo nes La ng LaSa lle Amer icas Faci lities M ana ge ment Service s Co ntract In 2009, Amgen signed an outsourcing agreement with Jones Lang LaSalle Americas for facilities management services. The facilities services contract applies to Amgens 11 North American sites, with most of the effect on facilities staff in Thousand Oaks, Calif., said company then spokesman David Polk. The company entered into a 5-year contract worth $500 million, Amgen reported in a filing with the U.S. Securities and Exchange Commission on Feb. 10. That contract includes services such as building and facilities maintenance, food services, waste disposal and recycling, inventory management of related supplies, utilities systems maintenance, and other projects. http://www.renalbusiness.com/hotnews/amgen-to-layoff-150-workers--outsource-facili.html Outs o ur ci ng R esea rc h a nd De sig n Strate gic O p eratio ns to I ndia In 2006, under the gun to increase productivity, Amgen opened up affiliates in Mumbai and Hong Kong. Amgen is embarking on the single greatest R&D expansion since the companys founding in 1980, declares Kevin Stark, former senior director, R&D Strategic Operations at Amgen. Mr. Stark says the company is adding new clinical capabilities around the world to keep up with what he calls Amgens robust pipeline. Its Mumbai operation will support trials in India while Hong Kongs serves as a regional hub for operations in East Asia. Amgen says it is partnering with companies in India and China to support its R&D operations, but wont divulge what its investing in Asia. http://www.redherring.com/Home/20098 Micr os oft S ha re Po int The following is an excerpt from a blog post dated 2009: Deploying software applications in a business driven organization is always a challenge. Here at Amgen we have started using Microsoft SharePoint as a way to increase peer-to-peer collaboration within large application deployment projects. Although still in the initial stages, we have experienced faster information sharing and better team convergence on new business processes. We are also working with secure Web content management service providers and our experience is that they can actually deliver on the promise of paperless document sharing with the added features of security and CFR 21 compliance. http://www.the-corner-office.com/2009/03/Web-20-business-service-erp-programs/ AR C HIBUS T otal I nfr astr uct ure and Facilitie s Ma na geme nt, A uto des k A ut oC AD Amgen selected ARCHIBUS for its predefined schema, flexibility, and compatibility with AutoCAD. The company was experiencing rapid expansion, particularly with the acquisition of Synergen in Boulder, Colo. Several scientists needed to be moved to Amgens headquarters in Thousand Oaks, Calif. Several others needed to be moved to Boulder. Relocating staff and reconfiguring space have been greatly facilitated by the CAFM system. Maintaining the system in the face of a 30 percent churn rate has been simplified by having human resources information downloaded automatically into the ARCHIBUS database. (Article dated 2005.) http://www.archibus.com/success/success_story.cfm?ssid=77
!
14
Amg en Lea n Busi nes s Strate gy Amgen developed a lean deployment strategy that took into consideration the relative youth of biotechnology, Amgens unique culture, and the recommendations of Lean experts. The team showed several million dollars in savings in the first six months and created enough positive momentum to widen the net in year two. (Article dated 2006.) http://www.qimacros.com/pdf/pharmabrochure.pdf P harm iWeb H os pitalP ha rma.c om Co llab orative P harma ceutic al P o rtal HospitalPharma.com, a new collaborative portal built by PharmiWeb Solutions, offers fast access to details on a wide range of pharmaceutical products. Hospital pharmacists can see price and prescribing information and then place orders, all through their desktop PC, via a standard Internet browser. The system also gives pharmaceutical companies a way to improve customer service without the cost of building and maintaining their own on-line systems. Amgen contracted to use the site in 2003. Paul Greenland, Business Unit Director of Amgen commented: We believe that this effective online channel for information, sales and support, will play a key role in helping us reach and support our secondary and tertiary care customer base (Article dated 2003.) http://www.microsoft.com/uk/press/content/presscentre/releases/2003/06/pr03084.mspx SA P S upp lier Relati o ns hip Ma nage ment (SRM ) 4. 0, Ariba 8.1, S pe nd Mana geme nt, S he lb y G ro up St rategic S oftwa re Co ns ulti ng Amgen employs two eProcurement systems covering worldwide indirect procurement. SAP/SRM 4.0 is used for all indirect procurement at Amgens European and Asia Pacific sites and for selected project related procurement activities in North America. Ariba 8.1 is used only at Amgens North American facilities for all remaining indirect procurement. With upgrades imminent for both SAP SRM and Ariba Spend Management, Amgen wanted to look closely at eProcurement in both new platforms to determine the optimal future strategy and direction of eProcurement. As a result, The Shelby Group was engaged to perform a strategic software assessment, which included an analysis of the financial viability of each software company, future product functionality, procurement best practices, software upgrade/implementation costs, and Return on Investment (ROI). (Undated case study.) http://www.theshelbygroup.com/client_success_amgen.html Amg en D ata Ce nte r Locati o ns Design firm Kling Stubbins lists the following Amgen projects, along with their locations, in its portfolio: Amgen AR6 Data Center design infrastructure build out West Greenwich, RI. Amgen Data Center upgrades Thousand Oaks, Calif. Amgen Information Technology Facility concept design Thousand Oaks, Calif. Amgen Information Technology Facility Juncos, Puerto Rico. http://www.klingstubbins.com/clientlist/clientlist_mission_critical.html

Maynar d Co nsulting: E ngi neered Standards Imp lementati o n To manage a rapidly evolving pipeline of new products effectively, Amgen recognized that developing new tools would not only help manage manufacturing capacity but would also support the continued success of its existing and new products. Amgen contracted H. B. Maynard and Company, Inc., an industrial engineering consulting firm, to facilitate the project. A cross-functional team of Amgen staff members and Maynard consultants was formed to
!
15
combine traditional and modern industrial engineering techniques to improve labor utilization, improve workflow, and increase overall output capacity. ( Undated article.) http://www.hbmaynard.com/ClientArticles/CSUpdate3.asp
Windo ws 20 0 3 Acti ve Di rect ory, NT 4. 0 Amgen hired the Active Directory, NIS+, and LDAP Architects from Structure Networks to perform the overall design, testing/validation, deployment and migration to a parallel Windows 2003 Active Directory infrastructure for over 18,000 users located at over 40 sites in North America, Europe, and Asia. Structure Networks also helped develop the strategy for migrating user accounts, security groups, client workstations and application servers from over 45 NT 4.0 domains to the Windows 2003 Active Directory infrastructure. (Undated case study.) http://www.structurenetworks.com/content.aspx?x=about_casestudies Ald o n A ppl icatio n Life cyc le Ma nage r, IBM i Se ri es, A S/ 4 00 Amgen must comply with strict FDA regulations, including the requirement to document and track all changes made to the AS/400 or iSeries systems and software. To help manage that process, Amgen uses Aldon Lifecycle Manager for iSeries, Aldons change management solution. The iSeries plays a crucial role in Amgens operations, running business applications ranging from financial management to manufacturing to sales and order processing. Amgen currently has three iSeries machines located in its corporate offices in Thousand Oaks. (Undated case study. Registration required for full article.) http://whitepapers.techrepublic.com.com/abstract.aspx?docid=167114 Que st Am erica Databa se Adm inistrati o n a nd Mainte na nce Se rvi ces, Oracl e App licati ons Databa se, NT infra struct ure Quest America is a CMMI Level 2, global full service Information Technology services firm that provides solutions through strategy, consulting, and outsourcing. The company provides database administration and maintenance services for Amgens Oracle Applications database on an NT infrastructure, with managed services SLAs to ensure application uptime and reliability. (Undated article.) http://www.questam.com/success.htm Glas sH o use Tec hno lo gie s IT I nfra struct ure C o ns ulti ng GlassHouse Technologies is an independent IT infrastructure consulting and services firm focused on transforming IT environments to a service provider model. Transom SM, GlassHouses proprietary methodology, aligns business processes and information technology systems, transforming our clients existing infrastructures into scalable, compliant, cost-efficient and tightly organized environments. In 2007, Glasshouse listed Amgen as a customer. http://news.thomasnet.com/companystory/534232 Oracle Sie bel Pharma D ynamic Sal es Oracles Siebel Pharma Dynamic Sales was specifically designed to meet the unique needs of the pharmaceutical and biotechnology industries. The application provides functionality for field sales and management, telesales, national accounts, medical affairs, customer service, and marketing organizations. Using built-in, easy-to-use analytics, the Siebel Pharma Dynamic Sales solution leverages customer and market intelligence gathered from multiple sources to better target physicians and maximize sales impact. Oracle listed Amgen as a customer of the Siebel solution in 2006. http://www.oracle.com/industries/life_sciences/siebel-pharma-dynamic-wp.pdf
!
16
Brai nwa re Data Sol uti o ns Brainware helps companies automatically extract, process, and retrieve data from any source. Their Data Capture solutions virtually eliminate manual data entry while their Enterprise Search solutions allow customers to locate required data more rapidly. Brainware listed Amgen as a customer. https://www.examiner.com/p330768~Premier_Oracle_Publication_Features_Brainware_Customer_Success_Story.html BCD Catap ult, i Se ries Business Computer Design Intl Inc. Catapult, the automated e-mail, portal and iSeries report distribution system, is utilized by Amgen. (Listed in 2004.) http://search400.techtarget.com/originalContent/0,289142,sid3_gci950787,00.html Intelex Safet y Ma na geme nt S ystem, i Fo rm s The Intelex Safety Management System is a Web-based software application that enables companies to practice pro-active and reactive safety management. Amgen uses Intelex Safety Management System with iForms. http://www.intelex.com/Manufacturing-28clients.aspx Pega s ystem s B us ine ss P roc es s Ma nage ment S oftwa re S ol uti ons Pegasystems provides Business Process Management (BPM) software solutions. They help organizations to achieve new levels of agility, become more competitive, and innovate. Pegasystems lists Amgen as a customer. http://www.pega.com/AboutPega/Customers/customer_detail.asp?c=11 S un a nd Inf o rmi x S ol utio ns Sun and Informix solutions: Solve operational problems and removing cost inefficiencies. Identify areas of business that need attention, and helping you determine what kind of attention they need. Enable companies to better understand their customers and their buying habits. Assist customers in running a more streamlined and profitable business. Sun listed Amgen as a customer in 1999. http://www.sun.com/third-party/dw/brochures/Sun_and_Informix_for_BI.pdf

IT EXECUTIVES
Tom Fl ana ga n, Se nio r Vic e P res ide nt a nd C hief Info rmati o n Off icer Tom Flanagan became senior vice president and CIO in September 2006. Prior to that, he led Amgens Global ERP program since February 2005. He joined Amgen in June 2004 as vice president, Information Systems. Prior to joining Amgen, Flanagan spent eight years at MCI, where he served in a variety of executive capacities, including CIO and senior vice president of Global Service Delivery. Before joining MCI in December 1995, Flanagan spent 24 years as an officer in the United States Navy. Flanagan is a graduate of the U.S. Naval Academy, MIT, U.S. Naval War College, and Harvard Universitys John F. Kennedy School of Government. http://www.amgen.com/about/leadership_team_tom_flanagan.html
!
17
Peter Flac k, Di recto r, Info rmati on S ystem s Infra structure Peter is currently serving two roles in Amgens Information Systems organization. He is accountable for Amgens data centers and computer rooms globally, where he is responsible for establishing a governance model for managing and operating these facilities as an enterprise resource. Peter is also a member of Amgens Global ERP Program Operations management team, focused on infrastructure architecture and deployment. Peter has been with Amgen for three years in various management roles focusing on infrastructure management and deployment. http://agendabuilder.gartner.com/lsc26/WebPages/SessionList.aspx?Speaker=1636
CRUSH Alerts Sales Triggers

SalesQuest is capable of delivering up-to-the-minute sales trigger alerts on your target accounts, industries and territories in a single, easy-to-read daily e-mail. For more information on how CRUSH Alerts can help increase productivity, save time, accelerate sales cycles and ensure that you dont miss out on any sales opportunities, please contact a SalesQuest representative at (978) 975-1111, ext. 102.
MILESTONES 2009 " 2008 " " 2007 " " " " "
August Named Dr. Fabrizio Bonanni as head of Operations. July Completed acquisition of Ilypsa. July Completes acquisition of Alantos. May Named David Lacey, M.D., Senior Vice President, Head of Research. April Appointed Robert Bradway as Executive Vice President and Chief Financial Officer. July Amgen and Ortho Biotech settled antitrust suit. June Named Anna Richo Senior Vice President of Worldwide Compliance. May Announced that it would lay off 101 workers at its drug-manufacturing site in Bothell, Wash. between July 13 and July 27, 2009.
!
18
Co mme ntar y f rom a Se ni o r B usi ne ss A nal yst based in J unc o s, P ue rto Rico. The team performs business process analysis, system upgrades and improvements, change control, project management, computer system validations, non-conformance investigations, and report generation using query tools such as Cognos Impromptu and Showcase. Projects performed include the following: Werum PAS-X 2.4 to 3.09 Team members performed gap analysis and master data management for an upgrade from version 2.4 to 3.09. The project involved analyzing and implementing business modifications utilized in the existing version into the new version. ERP Implementation (SAP) As part of this global project, the team managed data conversions from the ERP JDEdwards system into SAP. Group members translated business requirements into technical requirements, developed test scripts, and performed troubleshooting. OSISoft Plant Information (PI) and RtReports. The team administered the SCADA system at a bulk manufacturing plant at the site. Group responsibilities included translating business requirements/design into technical requirements/design, managing work orders and validation documents, training users on the RtReports application, and modifying system components. Oracle JD Edwards Single Instance Project. Group members participated in a global initiative to merge several databases from the ERP JD Edwards system into a single instance. They developed initial conversion programs for the merger of the data.
Co mme ntar y f rom an I nf or matio n S ystem s Ma na ger base d i n T ho usa nd Oak s, Calif. The Thousand Oaks technical team is tasked with implementing and supporting sales force incentive compensation and corporate competitive intelligence systems. They work closely with the business client (sales operations) to drive and streamline incentive compensation processes and procedures to meet overall corporate strategic goals and major product launches on time. Additional responsibilities include:
Partnering with the business client (business analytics and information group) to implement and support the competitive intelligence business system to achieve business marketing objectives and adhering to internally approved IS and business standards. Serving as technical experts of the Callidus TrueComp Suite, Actuate and Informatica technologies used in the incentive compensation processes, and integrating applications to use corporate directory services, Sun One Directory Server, and WebLogic Application Server. Performing technological gap analysis, system upgrade assessments and technical feasibility of new technologies to enable smooth integration with existing processes. Working with the vendors to incorporate custom code that enhances product functionalities to meet Amgen business needs. Performing project management activities, which include work effort estimation, resource allocation, budget preparation, client management and vendor relationship management.
!
19
Ensuring that all the compliance and approvals are met as per systems and audit guidelines.
The team led the TrueComp upgrade from version 3.7 to 5.1 and the assessment exercise. The hardware and software environment includes Informatica PowerCenter 7.1.2, 8.0; Actuate 7.1, 8.1; Oracle Database 9i, 10g; Microsoft SQL Server 2005; Callidus TrueComp 3.7 Suite, Sun Java System Web Server 6.1; Oracle PL/SQL, BEA Weblogic 8.1, Brio Intelligence 6.6; CA AllFusion ERwin 4.1; IBMI Rational Rose, RequisitePro; Visual Basic .NET, Sun Solaris 8,9; and Windows 2003 Servers.
Co mme ntar y f rom a Doc ume nt um De vel ope r ba sed i n Tho usa nd Oak s, Calif. The team participated in a project to implement EDM R&D (980.13), a system that will provide new, greatly improved document management processes, services, and infrastructure specifically tailored for document management. The EDM R&D subsystem uses Documentum as the repository manager for and the FirstDoc application software for the creation and management of controlled documents. Various FirstDoc applications were implemented into the system including EDM Quality and EDM Engineering, Webtop, and FDRD. The environment for this project included Content Server 5.3/6.5, FirstDoc R&D 4.3/6.0, Documentum Application Builder 5.3, DFC, DQL, WDK 5.3/6.5, WebTop 5.3/6.5, Documentum Administrator 5.3/6.5, Solaris, Oracle 10g, WebLogic 9.2, and Tomcat 5.
Co mme ntar y f rom an I nf or matio n S ystem s A ss o ciate base d i n T ho usa nd Oak s, C alif. Amgen implemented My Amgen using Oracle BEA Plumtree 4.5 and 5.0 Web software. There is a team in place that provides technical and analytical support for portal communities, with the responsibility of guiding clients through the community development process from requirements gathering to rolling out into production. The team acts as a point of contact for all development communities, including Medical Sciences, APECS, CTD Submissions, Epidemiology, Global Biostats, Process & Capacity Management, ICOG, Development Contract Management, AmgenTrials, CTAG, AGS, Commercialization and CTA. Amgen performed a department-wide cleanup of the IS registry metadata for development. This project involved meeting with business and system owners of current applications and updating all relevant information. The company put in place a point of contact for all IS registry updates, additions, and questions for development. The inventory is critical after business hours, as this is the place where the Help Desk would go to find out escalation contacts in a distaste recovery event. The company installed AmgenTrials clinical trial posting using the Web content management system, Silkroad Eprise. This site is vital for posting clinical trials that Amgen offers for patients participation.
Co mme ntar y f rom a B usi ne ss A nal yst base d i n Tho usa nd Oak s, Calif. Part of the responsibilities of the ACT1 business team is to facilitate secure, auditable and manageable collaboration between Amgen and its partners. Data is collected using Microsoft Access and Outlook and analyzed using NetScreen-Security Manager and HP Peregrine Systems, which is now HP OpenView. The team cross-referenced and updated the B2B Tracking Database from the original checklists in EDM Teams using Microsoft Access, Documentum and NetScreenSecurity Manager. Team members supported documentation, project scheduling and time management for the Extranet Project, and designed and implemented administrative reports for the Partner Identity Automation (PIDA) project for account provisioning of the Extranet Project using Microsoft SQL and Cognos.
!
20
Co mme ntar y f rom a Se ni o r S ystems A nal yst ba s ed in Los A ngeles , Ca lif. In response to the highly competitive biotechnology/pharmaceutical industry, Amgens IS department has created a competitive intelligence application that monitors the firms internal and external environment for information, enhancing the decision-making process. The group designed the Competitive Intelligence (CI) Application using Microsoft Visual Basic (VB) 6 and Microsoft .NET Framework in an environment that included Windows XP, COM+, IIS, ActiveX, XML, XSLT, DHTML, JavaScript, T-SQL, Stored Procedures, Visual SourceSafe and SQL Server 2000.
Co mme ntar y f rom a C o gno s C o ns ulta nt ba sed i n T ho usa nd Oak s, Calif. Amgen developed and implemented a Cognos Data Warehousing application divided into Sales Reporting and Activity Reporting for use by each division responsible to do reporting to multiple business units. Each business unit has multiple sales teams. The reports are developed using various Cognos BI tools such as Impromptu, Power Play, IWR, and Upfront, then published and distributed to end-users. Access Manager Administrator was used to provide security for the Cognos BI applications.
Co mme ntar y f rom a Pr oject Co o rdi nato r i n P roces s, Ope rati ons & Q ualit y, Info rmati o n S ystem Depa rtme nt, bas ed i n Tho usand Oa ks, Cali f. As a major biotechnology research and development house for a wide number of cancer- and other disease-treating drugs, Amgen has created an IS team that coordinates on a multi-site Laboratory Implementation Management System (LIMS) program and Scientific Data Management System (SDMS) program. This group is responsible for identifying project work streams, as well as providing stakeholders with relevant roles and responsibilities. The group develops and project plan schedules for site specific sub-projects using PMIS (Project Management Information System) and 3PS, or Project Portfolio Performance System, with Microsoft Project 2002 with Web access. Through these solutions, the IS department can track and update project financial information against project budget and yearly budget. They also can maintain an updated status of work stream in any project plan and facilitate weekly status update reports of each project work stream. The system makes it easier to forecast project budget. The group gathers and analyzes financial data using Oracle JD Edwards to determine overall internal and external costs and latest estimate, while preventing discrepancies within the budget. The system tracks invoices coming in for contract resources and the hardware and software purchased for the project. The team is able to set up meeting agendas, and then facilitate meetings, take meeting minutes and action items, and post documents in a Livelink or Documentum database to ensure communication and completion of action items. This also works strategically in implementing a project change control management process, project issue escalation process, or project decision flow.
Co mme ntar y f rom a C o ntract Ma na ge r ba sed i n Tho us and Oak s, Calif. Amgen contracts out a large number of IT jobs and roles to consultants in a full-time capacity. Some of the responsibilities include RFI/RFP, ROI analysis, business case development, vendor selection as well as the implementation and project management responsibilities for Integrated Document Management (IDM) System in support of finance operations and strategic sourcing. This particular contract group managed the implementation and testing of several Electronic Data Interchange (EDI) relationships with key vendors to reduce invoice count and transaction processing
!
21
costs. They also managed several Value Added Network providers including Advantis and GXS across multiple formats. They also ensure that all procurement practices are compliant with 2002 Sarbanes Oxley Act by developing new policies and procedures.
!
22
BOARD OF DIRECTORS
Name Age Yea r Elected Boa rds and Ot her Af filiati o ns Chairman of the Board; Former President of the Business Markets Division of MCI Communications Corporation; Formerly served in numerous executive capacities at General Electric Company; Director, Chevron Corporation and Northrop Grumman Corporation President Emeritus and Professor of Biology, California Institute of Technology; Former President of Caltech; Previously an Institute Professor at the Massachusetts Institute of Technology; Director of BB Biotech, AG, a Swiss investment company; Co-recipient of the Nobel Prize in Medicine Senior Managing Director of WaterView Advisors LLC; Formerly served as Chairman and Chief Executive Officer of Universal Studios, Inc.; Past President and CEO, Viacom, Inc.; Director, Cablevision Systems Corp., Hasbro, Inc., Seagate Technology and Yahoo! Inc.; Former Member of the board of directors of The Bank of New York Mellon Corporation Non-executive Chairman of the Board and director of Thomson S.A.; On the Boards of Pages Jaunes S.A. and of Quilvest S.A.; Ecofin Global Utilities Hedge Fund Ltd. and Ecofin North America Utilities Hedge Fund Ltd.; Served as Senior Advisor of the Global Corporate and Investment Bank of Citigroup; Past Managing Director and member of the Operating Committee, Global Corporate and Investment Bank of Citigroup; Served as Chairman and CEO, Midial S.A.; Formerly served as Chairman of General Electric Capital SNC; Past President, GE CapitalEurope, EVP of GE Capital and VP of GE; Former VP, Boston Consulting Group; French citizen and resides in Europe Former Chairman of the Board and CEO, The Allstate Corporation; Director, Valero Energy Corporation and serves on the Board of Trustees for the Van Kampen Mutual Funds Former Chairman of the Board and other executive positions at Amgen, Member of the National Academy of Engineering; Fellow in the American Institute of Aeronautics and Astronautics and the American Astronautical Society; Director, 3M Company and Deere & Company
Keith W. Sharer
61
2000
David Baltimore
71
1999
Frank J. Biondi, Jr.
64
2002
Franois de Carbonnel
63
2008
Jerry D. Choate
70
1998
Vance D. Coffman
64
2007
!
23
Frederick W. Gluck
73
1998
Frank C. Herringer
66
2004
Gilbert S. Omenn
67
1987
Judith C. Pelham
63
1995
Adm. J. Paul Reason, USN (Retired)
68
2001
Leonard D. Schaeffer
63
2004
Non-executive Chairman of the Board of CytomX Therapeutics, LLC and Cynvenio Biosystems LLC; Former managing partner, McKinsey & Company, Inc.; Former Vice Chairman and Director, Bechtel Group Formerly Chairman of the Board and CEO, Transamerica Corporation; Former Executive Board Director, Aegon N.V.; Past Chairman of the Board, Aegon U.S.A.; Director of The Charles Schwab Corporation and Safeway Inc. Professor of Internal Medicine, Human Genetics and Public Health at the University of Michigan; Former Dean of the School of Public Health and Community Medicine and Professor of Medicine at the University of Washington; Director, Rohm & Haas Co. and Armune BioScience, Inc. President Emeritus of Trinity Health; Sits on the board of trustees of Smith College; Former President and CEO, Trinity Health; Past President and CEO, Daughters of Charity Health Services, Austin, Texas Formerly served as Vice Chairman and Director, Metro Machine Corporation; Past President and COO, Metro Machine; Former U.S. Navy Four Star Admiral and Commander-In-Chief of the U.S. Atlantic Fleet; Served in numerous capacities, both at sea and ashore, in the U.S. Navy; Director of Norfolk Southern Corporation and Todd Shipyards Corporation Chairman of the Board of Surgical Care Affiliates, LLC and a Senior Advisor for Texas Pacific Group; Former Chairman of the Board of Directors, WellPoint Inc.; Formerly served as Chairman and CEO, WellPoint Health Networks Inc.; Former Administrator of the U.S. Health Care Financing Administration (now CMS); Member of the Institute of Medicine; Director of Allergan, Inc. and Quintiles Transnational Corp.
!
24
Fi rst Gale Lee Omer Todd Gina Charlie Keith David Peter Thomas Michael Andy Vicki Danny David Jon Reese Phil
Last Alcorn Allen Arman Barnum Beck Bonar Brown Christie Flack Flanagan Gabriel Gore Gottmer Hanie Hansen Hartman Hepburn Hoeh
Title Manager, Web & Collaboration Director, Web & Collaboration Services Web Portal System Analyst Director, Information Security Sr. Manager, Enterprise Systems Senior Manager, Information Systems VP, Enterprise Systems Director, Information Systems Director, Information Systems Infrastructure SVP and CIO Manager, Application Development Director, Web Communications Chief Information OfficerAssistant Manager Network/Telecom Director, Information Systems Director of Information Systems Management IT Audit Manager Director, Information Technology Sr. Manager, IS Service Management & Governance
P ho ne 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1915 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
E-Mail galcorn@amgen.com lallen@amgen.com oarman@amgen.com tbarnum@amgen.com gbeck@amgen.com cbonar@amgen.com kbrown@amgen.com david@amgen.com pflack@amgen.com tflanagan@amgen.com gabrielm@amgen.com agore@amgen.com vgottmer@amgen.com dhanie@amgen.com dhansen@amgen.com jon.hartman@amgen.com rhepburn@amgen.com treisej@amgen.com
Wendy
Holder
805-447-1000
wholder@amgen.com
!
25
Duane Sandra Hueb Jamie Vasudev
Howard Hueb Kiguchi Killada
Senior Associate IS Security Engineer Sr. Manager, Information Technology Director, Information Systems Teradata DBA and Architect Director of Information Systems, Solutions Architecture Website Administrator Director, Information Systems Sr. Manager, Web & Collaboration Services VP, Information Systems Executive Director, Information Systems Director of Global Business Intelligence and Master Data Management Director, Information Systems Director, Information Systems Director, Information Security and Compliance Sr. Manager, IS Disaster Recovery, Risk Management IS Business Systems Analyst Manager, Information Systems Manager, IS Data Center Operations Manager, IT Services (Siebel/Quality Assurance Testing Services) Manager, Information Systems IS Manager Network/Telecom Sr. Security Manager
805-447-1000 805-447-1000 805-447-1000 805-447-1000
dhoward@amgen.com shueb@amgen.com jkiguchi@amgen.com vkillada@amgen.com
Nancy Darryl Carmen Brian Diana Jan
Lehrer Levi Maronde McBreen Jr. McKenzie Meier
805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
nlehrer@amgen.com dlevi@amgen.com cmaronde@amgen.com bmcbreen@amgen.com dmckenzie@amgen.com jmeier@amgen.com
Jim Vadim Terri Thornton
Niehoff Parizher Parks Prime
805-447-1000 805-447-1000 805-447-1000 805-447-1000
jniehoff@amgen.com vparizher@amgen.com tparks@amgen.com tprime@amgen.com
Rick Todd Sandra Joan
Renshaw Rowe Sequeira Skelly
805-447-1000 805-447-1000 805-447-1000 805-447-1000
rrenshaw@amgen.com trowe@amgen.com ssequeira@amgen.com jskelly@amgen.com
Fred Joe Jim Bonnie
Sookiasian Soriano Stites Taylor
805-447-1000 805-447-7825 805-447-1000 805-447-1000
fsookiasian@amgen.com jsoriano@amgen.com jstites@amgen.com btaylor@amgen.com
!
26
Darlene Carmen Jason James radboud Chad Mike Denis
ThomasWoods Torres Viera Whiteley Wijnen Willard Zahigian Zerr
Director Information Systems Sr. Manager, Information Systems Network Architect Principal Infrastructure Architect CIO, International/Netherlands Sr. Manager IS, Network Services Director, Information Systems Executive Director, Operations IS
805-447-6866 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
darlenet@amgen.com ctorres@amgen.com jviera@amgen.com jwhiteley@amgen.com rwijnen@amgen.com cwillard@amgen.com mzahigian@amgen.com dzerr@amgen.com
!
27
Fi rst
Last
Nahed Ted Madhavan David W. Fabrizio Robert David Jacqueline S. Rodger James M.
Ahmed Bagley Balachandran Beier Bonanni Bradway Chang Crouse Currie Daly
Title VP, Project Management Research and Development VP, Human Resources SVP, Manufacturing SVP, Global Government and Corporate Affairs EVP, Operations EVP and CFO VP, Global Oncology Development VP, Taxes VP, Government Affairs SVP, North America Commercial Operations Media Contact Government Policy/Reimbursement Senior Manager Corporate Communications SVP and International Chief Medical Officer SVP, Global Regulatory Affairs and Safety Senior Director, Marketing Operations VP, Licensing Business Unit Director VP, Global Regulatory Affairs and Corporate Chief Medical Officer
P ho ne
E-Mail
805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
nahmed@amgen.com tbagley@amgen.com mbalachandran@amgen.com dbeier@amgen.com fbonanni@amgen.com rbradway@amgen.com dchang@amgen.com jcrouse@amgen.com rcurrie@amgen.com jdaly@amgen.com
Kelley Kristen Willard H. Paul R. Jeanne Scott J. Paul
Davenport Davis Dere Eisenberg Fitzgerald Foraker Greenland
805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
kdavenport@amgen.com kdavis@amgen.com wdere@amgen.com peisenberg@amgen.com jfitzgerald@amgen.com sforaker@amgen.com pgreenland@amgen.com
Sean E.
Harper
805-447-1000
sharper@amgen.com
!
28
Rolf K. Durk
Hoffmann Hubel
Ken Michael A. Mary David L. Jonathan Susanne Jean J. Brian M. Farryn Joseph P. Cara Alison George J. Connie Philip Joshua Susan Roger M.
Keller Kelly Klem Lacey Landon Laningham Lim McNamee Melton Miletich Miller Moore Morrow Murphree Noguchi Ofman ONeal Perlmutter
SVP, International Commercial Operations Senior Analyst, Investor Relations VP and General Manager, Inflammation Business Unit VP, Finance and Chief Accounting Officer Director, Corporate Communications SVP, Research Associate Director, Marketing Director, Business Analysis and Information President, Amgen Foundation SVP, Human Resources VP and Chief Procurement Officer SVP, Research and Development Director, Corporate Compliance Vice President Site Operations EVP, Global Commercial Operations Senior Manager Supplier Relationship Director, Regulatory Affairs VP, Reimbursement and Payment Policy Director, Human Resources EVP, Research and Development VP, Corporate Communications and Philanthropy Executive Director, Corporate Communications
805-447-1000 805-447-1000
rhoffmann@amgen.com dhubel@amgen.com
805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
kkeller@amgen.com mkelly@amgen.com mklem@amgen.com dlacey@amgen.com jlandon@amgen.com slaningham@amgen.com jlim@amgen.com bmcnamee@amgen.com fmelton@amgen.com jmiletich@amgen.com cmiller@amgen.com amoore@amgen.com gmorrow@amgen.com cmurphree@amgen.com pnoguchi@amgen.com jofman@amgen.com soneal@amgen.com rperlmutter@amgen.com
Phyllis J.
Piano
805-447-1000
ppiano@amgen.com
David
Polk
805-447-1000
dpolk@amgen.com
!
29
Sari H. Christine Anna S. Jill Steven J. David J. Kevin W. Geoffrey F. Arvind K. Helen
Ratican Regan Richo Rogers Schoch Scott Sharer Slaff Sood Torley
Chief Privacy Officer, Worldwide Compliance & Business Ethics Media Contact SVP and Chief Compliance Officer Executive Director VP, Finance SVP, General Counsel and Secretary Chairman, President and CEO VP, Quality VP, Investor Relations VP and General Manager, Nephrology
805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000
sratican@amgen.com cregan@amgen.com aricho@amgen.com jrogers@amgen.com sschoch@amgen.com dscott@amgen.com ksharer@amgen.com gslaff@amgen.com asood@amgen.com htorley@amgen.com
!
30
!
31
!
32
CRUSH Report! is a trademark and the property of SELIGENCE, LLC. The information contained in CRUSH Report was compiled by SELIGENCE, LLC from public sources (the information). The information has not been verified by SELIGENCE, LLC. It is understood that SELIGENCE, LLC is not responsible for the accuracy of the information. The sale of CRUSH Report by parties other than SELIGENCE, LLC is prohibited. SELIGENCE, LLC clients may not forward or distribute CRUSH Report to third parties.
!
33

Amgen - CRUSH Report - 09B2

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Amgen - CRUSH Report - 09B2

Caricato da

Copyright:

Formati disponibili

!

INFORMATION TECHNOL OGY HIGHLIGHTS

EARNINGS CALL TRANSCRIPT

(Case study dated 2008.) http://www.cwhonors.org/viewCaseStudy2008.asp?NominationID=2031

CRUSH Alerts Sales Triggers

Frank J. Biondi, Jr.

Adm. J. Paul Reason, USN (Retired)

Duane Sandra Hueb Jamie Vasudev

Howard Hueb Kiguchi Killada

805-447-1000 805-447-1000 805-447-1000 805-447-1000

dhoward@amgen.com shueb@amgen.com jkiguchi@amgen.com vkillada@amgen.com

Nancy Darryl Carmen Brian Diana Jan

Lehrer Levi Maronde McBreen Jr. McKenzie Meier

805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000

nlehrer@amgen.com dlevi@amgen.com cmaronde@amgen.com bmcbreen@amgen.com dmckenzie@amgen.com jmeier@amgen.com

Jim Vadim Terri Thornton

Niehoff Parizher Parks Prime

805-447-1000 805-447-1000 805-447-1000 805-447-1000

jniehoff@amgen.com vparizher@amgen.com tparks@amgen.com tprime@amgen.com

Rick Todd Sandra Joan

Renshaw Rowe Sequeira Skelly

805-447-1000 805-447-1000 805-447-1000 805-447-1000

rrenshaw@amgen.com trowe@amgen.com ssequeira@amgen.com jskelly@amgen.com

Fred Joe Jim Bonnie

Sookiasian Soriano Stites Taylor

805-447-1000 805-447-7825 805-447-1000 805-447-1000

fsookiasian@amgen.com jsoriano@amgen.com jstites@amgen.com btaylor@amgen.com

Darlene Carmen Jason James radboud Chad Mike Denis

ThomasWoods Torres Viera Whiteley Wijnen Willard Zahigian Zerr

805-447-6866 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000

darlenet@amgen.com ctorres@amgen.com jviera@amgen.com jwhiteley@amgen.com rwijnen@amgen.com cwillard@amgen.com mzahigian@amgen.com dzerr@amgen.com

Kelley Kristen Willard H. Paul R. Jeanne Scott J. Paul

Davenport Davis Dere Eisenberg Fitzgerald Foraker Greenland

805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000 805-447-1000

kdavenport@amgen.com kdavis@amgen.com wdere@amgen.com peisenberg@amgen.com jfitzgerald@amgen.com sforaker@amgen.com pgreenland@amgen.com

Potrebbero piacerti anche